Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

35.29
+0.59351.71%
Post-market: 35.380.0865+0.25%16:00 EDT
Volume:148
Turnover:5K
Market Cap:16.59M
PE:- -
High:35.29
Open:35.23
Low:35.23
Close:34.70
52wk High:37.90
52wk Low:30.79
Shares:469.95K
Float Shares:469.95K
Volume Ratio:0.41
T/O Rate:0.03%
Dividend:0.41
Dividend Rate:1.16%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period

THOMSON REUTERS
·
Sep 30

Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity

THOMSON REUTERS
·
Sep 30

AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss up to About 10% over 3-Month Period

Reuters
·
Sep 30

ETF Daily Report (09.30): ESMO Data Expectations and BD Momentum Lift Vaccine and Innovative Drug Sectors, Semiconductor Stocks Retreat Broadly

Stock News
·
Sep 30

AbbVie Says Mid-Stage Study of Atopic Dermatitis Treatment Meets Primary Goal

MT Newswires Live
·
Sep 30

Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026

THOMSON REUTERS
·
Sep 30

AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026

Reuters
·
Sep 30

Mayne Pharma Secures Long-Term IMVEXXY Patent Protection in U.S. Settlement With Sun Pharma

TIPRANKS
·
Sep 30

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

GlobeNewswire
·
Sep 30

Eli Lilly reports results from TRIUMPH-2 Phase 3 trial

TIPRANKS
·
Sep 30

Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial

Reuters
·
Sep 30

Eli Lilly - Retatrutide 12 Mg Results in 49.6 Lb (20.8%) Weight Loss over 80 Weeks

THOMSON REUTERS
·
Sep 30

Lilly's Triple Agonist, Retatrutide, Delivered Substantial Weight Loss and A1c Reduction, Underscoring Its Potential Promise for People with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly - to Submit Biologics License Application for Retatrutide in Q1 2027

THOMSON REUTERS
·
Sep 30

Eli Lilly - 59.5% of Retatrutide 12 Mg Participants no Longer Meet Bmi Criteria for Obesity

THOMSON REUTERS
·
Sep 30

AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 30

Liver safety concerns emerge for Bristol Myers’ admilparant, says Wells Fargo

TIPRANKS
·
Sep 30

Johnson: AI Providers Committed to Building Trust

THOMSON REUTERS
·
Sep 30

Johnson: We Can Keep Edge in a Safe Way

THOMSON REUTERS
·
Sep 30

Johnson: We'LL Continue to Assess and Deliberate in Coming Days

THOMSON REUTERS
·
Sep 30